Compare Bristol-Myers Squibb Co (BMY) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Krispy Kreme Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.98 (market cap $116.30B), while Krispy Kreme Inc trades at $3.36 (market cap $574.09M). The key difference: Bristol-Myers Squibb Co is far larger — about 202.6× Krispy Kreme Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | DNUT | |
|---|---|---|
Market Cap | $116.30B | $574.09M |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $4.70 |
52-Week Low | $42.60 | $2.92 |
Enterprise Value | $152.24B | $1.77B |
Dividend Yield | 4.42% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Krispy Kreme (DNUT) trades at $3.47, up 0.87% today, with a bearish technical signal and mixed earnings history. The company reported a net loss of $515.77M in 2025 despite a gross margin of 75.56%, while analyst consensus leans bullish with 50% buy ratings. Recent news highlights strategic pivots to capital-light models and seasonal product launches to drive engagement.
Outlook remains challenged by persistent losses and high debt, but positive free cash flow in Q1 2026 and international growth potential offer catalysts. Key risks include execution on turnaround plans and competitive pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
